These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 11751380)

  • 1. A Xeroderma pigmentosum group D gene polymorphism predicts clinical outcome to platinum-based chemotherapy in patients with advanced colorectal cancer.
    Park DJ; Stoehlmacher J; Zhang W; Tsao-Wei DD; Groshen S; Lenz HJ
    Cancer Res; 2001 Dec; 61(24):8654-8. PubMed ID: 11751380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Polymorphisms in nucleotide excision repair genes XPC and XPD and clinical responses to platinum-based chemotherapy in advanced non-small cell lung cancer].
    Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Sun Y; Xu BH; Lin DX
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):972-5. PubMed ID: 16061005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of the DNA repair gene XPD Asp312Asn polymorphism with p53 gene mutations in tobacco-related non-small cell lung cancer.
    Gao WM; Romkes M; Day RD; Siegfried JM; Luketich JD; Mady HH; Melhem MF; Keohavong P
    Carcinogenesis; 2003 Oct; 24(10):1671-6. PubMed ID: 12844488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ERCC1 gene polymorphism as a predictor for clinical outcome in advanced colorectal cancer patients treated with platinum-based chemotherapy.
    Park DJ; Zhang W; Stoehlmacher J; Tsao-Wei D; Groshen S; Gil J; Yun J; Sones E; Mallik N; Lenz HJ
    Clin Adv Hematol Oncol; 2003 Mar; 1(3):162-6. PubMed ID: 16224397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
    Gurubhagavatula S; Liu G; Park S; Zhou W; Su L; Wain JC; Lynch TJ; Neuberg DS; Christiani DC
    J Clin Oncol; 2004 Jul; 22(13):2594-601. PubMed ID: 15173214
    [TBL] [Abstract][Full Text] [Related]  

  • 6. XPD codon 751 polymorphism, metabolism genes, smoking, and bladder cancer risk.
    Stern MC; Johnson LR; Bell DA; Taylor JA
    Cancer Epidemiol Biomarkers Prev; 2002 Oct; 11(10 Pt 1):1004-11. PubMed ID: 12376500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy.
    Ryu JS; Hong YC; Han HS; Lee JE; Kim S; Park YM; Kim YC; Hwang TS
    Lung Cancer; 2004 Jun; 44(3):311-6. PubMed ID: 15140544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Relationship between single nucleotide polymorphism in repair gene XPD751 and prognosis in colorectal carcinoma patients].
    Chen YM; Wu XL; Zhang LW; Xu X; Liu JW
    Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):501-5. PubMed ID: 22967467
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The combination of ERCC1 and XRCC1 gene polymorphisms better predicts clinical outcome to oxaliplatin-based chemotherapy in metastatic colorectal cancer.
    Liang J; Jiang T; Yao RY; Liu ZM; Lv HY; Qi WW
    Cancer Chemother Pharmacol; 2010 Aug; 66(3):493-500. PubMed ID: 19960344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFOX-4 chemotherapy.
    Ruzzo A; Graziano F; Loupakis F; Rulli E; Canestrari E; Santini D; Catalano V; Ficarelli R; Maltese P; Bisonni R; Masi G; Schiavon G; Giordani P; Giustini L; Falcone A; Tonini G; Silva R; Mattioli R; Floriani I; Magnani M
    J Clin Oncol; 2007 Apr; 25(10):1247-54. PubMed ID: 17401013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ERCC1 codon 118 polymorphism is a predictive factor for the tumor response to oxaliplatin/5-fluorouracil combination chemotherapy in patients with advanced colorectal cancer.
    Viguier J; Boige V; Miquel C; Pocard M; Giraudeau B; Sabourin JC; Ducreux M; Sarasin A; Praz F
    Clin Cancer Res; 2005 Sep; 11(17):6212-7. PubMed ID: 16144923
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer.
    Zhou W; Liu G; Miller DP; Thurston SW; Xu LL; Wain JC; Lynch TJ; Su L; Christiani DC
    Cancer Res; 2002 Mar; 62(5):1377-81. PubMed ID: 11888908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in XPD exons 10 and 23 and bladder cancer risk.
    Schabath MB; Delclos GL; Grossman HB; Wang Y; Lerner SP; Chamberlain RM; Spitz MR; Wu X
    Cancer Epidemiol Biomarkers Prev; 2005 Apr; 14(4):878-84. PubMed ID: 15824159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Xeroderma pigmentosum group D haplotype predicts for response, survival, and toxicity after platinum-based chemotherapy in advanced nonsmall cell lung cancer.
    Booton R; Ward T; Heighway J; Taylor P; Power F; Ashcroft L; Morris J; Thatcher N
    Cancer; 2006 Jun; 106(11):2421-7. PubMed ID: 16649224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
    Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
    J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymorphisms in the DNA repair gene XPD and susceptibility to esophageal squamous cell carcinoma.
    Yu HP; Wang XL; Sun X; Su YH; Wang YJ; Lu B; Shi LY; Xiong CL; Li YY; Li F; Xu SQ
    Cancer Genet Cytogenet; 2004 Oct; 154(1):10-5. PubMed ID: 15381366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study.
    Liu D; O'Day SJ; Yang D; Boasberg P; Milford R; Kristedja T; Groshen S; Weber J
    Clin Cancer Res; 2005 Feb; 11(3):1237-46. PubMed ID: 15709194
    [TBL] [Abstract][Full Text] [Related]  

  • 19. XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk.
    Liu G; Zhou W; Yeap BY; Su L; Wain JC; Poneros JM; Nishioka NS; Lynch TJ; Christiani DC
    Carcinogenesis; 2007 Jun; 28(6):1254-8. PubMed ID: 17264068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy.
    Shen M; Hung RJ; Brennan P; Malaveille C; Donato F; Placidi D; Carta A; Hautefeuille A; Boffetta P; Porru S
    Cancer Epidemiol Biomarkers Prev; 2003 Nov; 12(11 Pt 1):1234-40. PubMed ID: 14652287
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.